GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » Shiller PE Ratio

IRLAB Therapeutics AB (OSTO:IRLAB A) Shiller PE Ratio : (As of Jul. 22, 2025)


View and export this data going back to 2017. Start your Free Trial

What is IRLAB Therapeutics AB Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


IRLAB Therapeutics AB Shiller PE Ratio Historical Data

The historical data trend for IRLAB Therapeutics AB's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRLAB Therapeutics AB Shiller PE Ratio Chart

IRLAB Therapeutics AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

IRLAB Therapeutics AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of IRLAB Therapeutics AB's Shiller PE Ratio

For the Biotechnology subindustry, IRLAB Therapeutics AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IRLAB Therapeutics AB's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where IRLAB Therapeutics AB's Shiller PE Ratio falls into.


;
;

IRLAB Therapeutics AB Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

IRLAB Therapeutics AB's E10 for the quarter that ended in Mar. 2025 is calculated as:

For example, IRLAB Therapeutics AB's adjusted earnings per share data for the three months ended in Mar. 2025 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.614/132.8245*132.8245
=-0.614

Current CPI (Mar. 2025) = 132.8245.

IRLAB Therapeutics AB Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 0.000 100.541 0.000
201412 0.000 100.225 0.000
201512 0.000 100.276 0.000
201603 -0.469 100.751 -0.618
201606 -0.239 101.019 -0.314
201609 -0.390 101.138 -0.512
201612 -0.535 102.022 -0.697
201703 -0.367 102.022 -0.478
201706 -0.282 102.752 -0.365
201709 -0.549 103.279 -0.706
201712 -0.343 103.793 -0.439
201803 -0.419 103.962 -0.535
201806 -0.603 104.875 -0.764
201809 -0.071 105.679 -0.089
201812 -0.426 105.912 -0.534
201903 -0.423 105.886 -0.531
201906 -0.696 106.742 -0.866
201909 -0.492 107.214 -0.610
201912 -0.642 107.766 -0.791
202003 -0.397 106.563 -0.495
202006 -0.510 107.498 -0.630
202009 -0.519 107.635 -0.640
202012 -0.378 108.296 -0.464
202103 -0.368 108.360 -0.451
202106 -0.481 108.928 -0.587
202109 2.219 110.338 2.671
202112 -0.425 112.486 -0.502
202203 -0.529 114.825 -0.612
202206 -0.491 118.384 -0.551
202209 -0.434 122.296 -0.471
202212 -0.604 126.365 -0.635
202303 -1.086 127.042 -1.135
202306 -0.821 129.407 -0.843
202309 -0.699 130.224 -0.713
202312 -0.633 131.912 -0.637
202403 -0.708 132.205 -0.711
202406 -0.132 132.716 -0.132
202409 -0.576 132.304 -0.578
202412 -0.094 132.987 -0.094
202503 -0.614 132.825 -0.614

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


IRLAB Therapeutics AB  (OSTO:IRLAB A) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


IRLAB Therapeutics AB Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of IRLAB Therapeutics AB's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


IRLAB Therapeutics AB Business Description

Traded in Other Exchanges
N/A
Address
Arvid Wallgren Backe 20, Goteborg, SWE, 413 46
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

IRLAB Therapeutics AB Headlines

No Headlines